Clinical features of acute viral hepatitis A complicated with acute renal failure  by Choi, H. et al.
e th In
i
(
t
i
o
(
g
e
a
r
i
m
p
O
r
r
a
r
s
(
a
2
t
l
m
t
p
g
t
p
d
d
5
C
w
H
J
l
l
s
f
i
t
(
p
r
J
s
d
h
p
t
a
w
b
c
o
(
P
C
5
d
p
(
a
T
a
e
i
a
h
P
9
t
A
h
h
w
c
d
5
P
i
M
A
A
1
R
2
R
3
(
4
o
5
6
R
7
a
a
o
s
H226 14
ng liver cirrhosis and/or liver cancer. Occult hepatitis C virus
OCV) infection is characterized by presence of HCV infec-
ion with undetectable hepatitis C antibodies or/and RNA
n serum. Scanty information is available about the etiology
f viral chronic liver diseases in the United Arab Emirates
UAE). Therefore a study was carried out for detecting and
enotyping of HCV & OCV in patients with chronic liver dis-
ase (CLD) in UAE.
Methods: A total of 142 serum samples from CLD patients
nd 139 healthy individuals were tested by polymerase chain
eaction (PCR) & (RT-PCR) in determining HCv RNA&HBVDNA
n serum samples. ELISA tests were used to detect HCV & HBV
arkers in patient sera. Liver biopsies were taken from CLD
atients for immunohistochemistry((IHC) staining.
Results: The results indicated the prevalence of HCV,
ccult HCV, dual (HBV &HCV) and HBV infections at a
ate of 43.7%, 27.5%, 19.0% and 12.7% in CLD patients
espectively. Were as Healthy subjects were positive for
nti body HCV and HBV-DNA at a rate of 3.6% and 2.2%
espectively (P = 0.001). The most prevalent genotypes and
ubtypes of of HCV infection in CDL patients were genotype 4
28.3%),Where as the prevalence of other genotypes,3a,1a,
nd 3b,1b, 5, 2, 3a & 3b, 2a and 1a & 1b were in the range of
5.3 to 1.3%. IHC results for HCV in biopsy tissues revealed
hat 84.6 (11/13) were positive. Histopathological studies of
iver biopsies revealed that patients with HCV infection were
ore likely to have necroinﬂammatory activity and ﬁbrosis
han patients without HCV infection.
Conclusion: Occult HCV is relatively frequent among
atients with CLD in the UAE. Phylogenetic tree showed that
enotype 4 appears to be the dominant genotype Where as
he prevalence of other genotypes that circulating in UAE
opulation.(1b, 5, 2, 3a & 3b, 2a and 1a &1b) were less
ominant than genotype 4.
oi:10.1016/j.ijid.2010.02.1990
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Background: Although acute hepatitis A is usually self-
imited, the clinical manifestations can vary from mild to
evere liver dysfunction. However, little is known about risk
actors and outcome predictors for acute renal failure (ARF)
n acute hepatitis A. The objective of this study was to iden-
ify the simple clinical predictors for acute renal failure
ARF) and its clinical course.
Methods: The study and control groups consisted of
atients who did or did not develop acute renal failure,
espectively, after acute hepatitis A from January 2006 to
une 2009. A total of 396 patients were enrolled in this
tudy. We conducted a retrospective analysis of the inci-
ence, risk factors, and outcomes of patients with acute
epatitis A complicated with ARF.
Results: Thirty patients (7.6%) developed ARF. Older
atients and males were more likely to ARF during hepati-
a
a
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is A. ARF patients were more likely obese, heavy alcoholics
nd having fulminant course. The ARF patients had a higher
hite blood cell count, higher levels of AST, ALT, total
ilirubin and CRP, lower levels of albumin, more frequent
oagulopathy, and lower platelet count compared with the
thers. On multivariate analysis, male gender [Odds ratio
OR) 9.616, 95% conﬁdence interval (CI) 1.307—70.000,
= 0.026], the presence of hypertension [OR 5.91, 95%
I 1.407-24.824, P = 0.015] and fulminant hepatitis [OR
7.95, 95% CI 10.399—322.928, P < 0.001] were indepen-
ent risk factors of hepatitis A-associated ARF. Of the 30
atients with ARF, 23 (76.7%) patients fully recovered; 14
46.7%) patients recovered with conservative care only,
nd nine (30%) patients required short-term hemodialysis.
he two groups of spontaneous recovery from ARF (n = 14)
nd hemodialysis/death (n = 16) showed signiﬁcant differ-
nces in platelet count at its worst value, creatinine at
ts worst value, albumin at admission, INR at admission
nd fulminant hepatic failure. Albumin level at admission
igher than 3.6mg/dL [OR 13.183, 95% CI 1.064-163.403,
= 0.045] and INR at admission less than 1.6 [OR 14.969,
5% CI 1.346-166.447, P = 0.028] were independent predic-
ors of spontaneous recovery of ARF during acute hepatitis
.
Conclusion: Acute renal failure associated with acute
epatitis A is not a rare complication. Male gender and
ypertension are risk factors of ARF. Patients complicated
ith ARF, higher albumin level and shorter INR at admission
ould a favorable prognostic factor.
oi:10.1016/j.ijid.2010.02.1991
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Background: Prevalence of hepatitis B virus (HBV), hep-
titis C virus (HCV) and co-infection of HBV and HCV are high
mong injection drug users. Hepatitis B may be presented
nly with isolated Hepatitis B core antibody (anti-HBc). This
tudy aimed to determine the prevalence of isolated anti-
Bc among injection drug users in central province of Iran
nd comparison of its prevalence with healthy blood donors.
Methods: A total of 531 voluntary blood donors with mean
ge of 36± 10.18 years (range 16—60 years) and 153 injec-
ion drug users with mean age of 30.66± 5.92 years (range
